Table 1 PFS according to combination of IGHV gene mutational status, TL and CD49d expression.

IGHV	TL	CD49d	Patients	PFS^a				HR (95% CI)^b
IGHV	TL	CD49d	Patients	1 year	2 years	5 years	8 years
ARCTIC-ADMIRE cohort
UNMUT			132	96.2%	88.6%	47.0%	19.0%	5.58 (3.70–8.42)
MUT	TL-IFR		13	100%	84.6%	30.8%	15.4%	6.45 (1.84–22.58)
MUT	TL-OFR	Pos	33	93.8%	84.1%	64.7%	43.1%	2.52 (1.08–5.89)
MUT	TL-OFR	Neg	38	100%	94.6%	83.8%	75.5%	Reference
UK CLL4 cohort
UNMUT			59	81.4%	66.1%	27.1%	5.4%	6.81 (4.04–11.46)
MUT	TL-IFR		20	90.0%	80.0%	15.0%	0.0%	6.27 (2.75–14.32)
MUT	TL-OFR	Pos	7	85.7%	85.7%	42.9%	21.4%	3.08 (0.73–13.02)
MUT	TL-OFR	Neg	18	100%	100%	77.8%	77.8%	Reference

PFS progression-free survival, IGHV immunoglobulin heavy chain variable, TL telomere length, HR hazard ratio, CI confidence interval, UNMUT UM-IGHV gene mutational status, MUT M-IGHV gene mutational status, TL-ORF telomere length outside fusogenic range, TL-IFR telomere length inside fusogenic range, Neg negative (i.e. CD49d < 30% of positive cells), Pos positive (i.e. CD49d ≥ 30% of positive cells).
^aEstimated through the Kaplan–Meier method.
^bEstimated from Cox proportional hazard model.

Quick links

Search